PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Anticoagulation in Patients With Venous Thromboembolism and Cancer
- Conditions
- NeoplasmsEmbolism
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04618913
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT04617275
- Locations
- 🇺🇸
Emerson Clinical Research Institute, Washington, District of Columbia, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸Solaris Clinical Research, Meridian, Idaho, United States
STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT04616339
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
- Conditions
- Diabetes Mellitus, Type 2HealthyRenal Impairment
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT04616027
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸University of Miami Hospital, Miami, Florida, United States
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
- Conditions
- Community Acquired Pneumonia (CAP)
- Interventions
- Diagnostic Test: Urine sample collectionDiagnostic Test: Saliva collection
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1786
- Registration Number
- NCT04613375
- Locations
- 🇪🇸
Hospital Universitario de Mostoles, Mostoles, Madrid, Spain
🇪🇸Hospital Universitarios De Getafe, Getafe, Madrid, Spain
🇪🇸Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT04609319
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 234
- Registration Number
- NCT04607837
- Locations
- 🇺🇸
Tampa Bay Endoscopy Center, Tampa, Florida, United States
🇺🇸Pulmonary and Critical Care Medicine Associates (PFT only), Lemoyne, Pennsylvania, United States
🇺🇸Harrisburg Eye Associates (OCT only), Harrisburg, Pennsylvania, United States
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 816
- Registration Number
- NCT04607421
- Locations
- 🇺🇸
LAC & USC Medical Center, Los Angeles, California, United States
🇺🇸Cedars- Sinai Medical Center, Los Angeles, California, United States
🇺🇸Investigational Drug Service, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced or Metastatic Non-small Cell Lung CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic ER+ HER2- Breast Cancer
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 186
- Registration Number
- NCT04606446
- Locations
- 🇺🇸
Thomas Jefferson University, Gibbon Building, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Investigational Drug Service, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia, Pennsylvania, United States
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT04604496
- Locations
- 🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States